Document is current
Any future updates will be listed below
-
Authors
Willerslev-Olsen, Andreas
Buus, Terkild B. https://orcid.org/0000-0001-7180-6384
Nastasi, Claudia
Blümel, Edda
Gluud, Maria
Bonefeld, Charlotte M. https://orcid.org/0000-0002-0523-6229
Geisler, Carsten https://orcid.org/0000-0002-8472-0771
Lindahl, Lise M.
Vermeer, Maarten
Wasik, Mariusz A.
Iversen, Lars
Becker, Jürgen C.
Andersen, Mads Hald
Gjerdrum, Lise M. R.
Litvinov, Ivan V. https://orcid.org/0000-0003-0562-4675
Litman, Thomas https://orcid.org/0000-0002-6068-901X
Krejsgaard, Thorbjørn
Woetmann, Anders https://orcid.org/0000-0002-3008-735X
Ødum, Niels
-
Funding
Funding for this research was provided by:
Lundbeckfonden
- License Information
-
More Information
Article History
Received: 6 November 2019
Revised: 28 January 2020
Accepted: 4 February 2020
First Online: 14 May 2020
Conflict of interest
: N.Ø. has advisory consultant honoraria from Micreos human Health B.V. J.C.B. has received speaker honoraria from Amgen, Merck Serono, Sanofi, and Pfizer, advisory board honoraria from 4SC, Amgen, CureVac, eTheRNA, Lytix, Merck Serono, Novartis, ReProTher, Rigontec, and Sanofi, as well as research funding from Alcedis, Amgen, Bristol-Myers Squibb, IQVIA, and Merck Serono; he also received travel support from 4SC and Incyte. L.M.R.G. receives funding from NanoString Technologies and travel support from Gilead. T.L. is funded by LEO Pharma A/S. The remaining authors declare that they have no conflict of interest.
